Sorrento Therapeutics Inc. announced that it has acquired the exclusive rights to Cynviloq in Australia, Canada and Mexico from Samyang Biopharmaceuticals, a South Korean corporation. Sorrento has the exclusive rights to Samyang's Cynviloq (marketed as Genexol-PM in South Korea and other countries) in the US and the 27 countries of the EU. According to the company, Cynviloq (IG-001; a paclitaxel-loaded micellar diblock copolymer) is a next-generation branded paclitaxel formulation for the potential treatment of metastatic breast cancer, non-small cell lung cancer, pancreatic cancer and other solid tumors.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
69,400 KRW | +0.87% | +1.31% | +0.58% |
1st Jan change | Capi. | |
---|---|---|
+0.58% | 387M | |
-4.93% | 265B | |
-0.83% | 96.62B | |
+4.52% | 46.98B | |
+7.81% | 39.65B | |
-0.10% | 40.34B | |
+3.23% | 39.3B | |
-15.97% | 30.45B | |
-5.77% | 29.01B | |
+12.75% | 24.9B |
- Stock Market
- Equities
- A000070 Stock
- News Samyang Holdings Corporation
- Sorrento Therapeutics Acquires the Exclusive Rights to Cynviloq to Expand into Australia, Canada and Mexico